Current developments in understanding of West Nile virus central nervous system disease

Current Opinion in Neurology

Volumn 27, Issue 3, 2014, Pages 342-348

  Tyler, Kenneth L ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

acute flaccid paralysis; antiviral therapy; encephalitis; meningitis; vaccine; West Nile virus

Indexed keywords

ALPHA INTERFERON; DENGUE VACCINE; FAVIPIRAVIR; MEASLES VACCINE; VIRUS ANTIBODY; WEST NILE VACCINE; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CANCER IMMUNIZATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; EPIDEMIC; FLAVIVIRUS INFECTION; FLUORESCENCE ANGIOGRAPHY; HUMAN; INNATE IMMUNITY; MOLECULAR EPIDEMIOLOGY; NEUROIMMUNOLOGY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; UNITED STATES; VIRUS ISOLATION; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ANTIVIRAL AGENTS; EPIDEMICS; HUMANS; UNITED STATES; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84900505762     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000088     Document Type: Review

References (64)

1. Centers for Disease Control and Prevention (CDC). West Nile virus and other arboviral diseases-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:513-517.
2. Roehrig JT. West Nile virus in the United States: a historical perspective. Viruses 2013; 10:3088-3108.
3. Beasley DW, Barrett AD, Tesh RB. Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done? Antiviral Res 2013; 99:1-5.
4. Barzon L, Pacenti M, Franchin E, et al. Large outbreak of West Nile virus infection in north-eastern Italy in 2012. Viruses 2013; 5:2825-2839.
5. Pem-Novosel I, Vilibic-Cavlek T, Gjenero-Margan I, et al. First outbreak of West Nile virus neuroinvasive disease in humans, Croatia, 2012. Vector Borne Zoonotic Dis 2014; 14:82-84.
6. Donadieu E, Bahuon C, Lowenski S, et al. Differential virulence and pathogenesis of West Nile viruses. Viruses 2013; 5:2856-2880.
7. Mann BR, McMullen AR, Swetnam DM, Barrett AD. Molecular epidemiology and evolution of West Nile virus in North America. Intl J Environ Res Public Health 2013; 10:5111-5129.
8. Lindsey NP, Staples JE, Delorey MJ, Fischer M. Lack of evidence of increased West Nile virus severity in the United States in 2012. Am J Trop Med Hyg 2014; 90:163-168.
9. Duggal NK, D'Anton M, Xiang J, et al. Sequence analysis of 2012 West Nile virus isolates from Texas fail to associate viral genetic factors with outbreak magnitude. Am J Trop Med Hyg 2013; 89:205-210.
10. Prow NA. The changing epidemiology of Kunjin virus in Australia. Int J Environ Res Public Health 2013; 10:6255-6272.
11. Kilpatrick AM, Pape WJ. Predicting West Nile virus infections with mosquito surveillance data. Am J Epidemiol 2013; 178:829-835.
12. Rabe IB, Schwartz BS, Farnon EC, et al. Fatal transplant-associated West Nile virus encephalitis and public health investigation-California 2010. Transplantation 2013; 96:463-468.
13. Centers for Disease Control and Prevention (CDC). Fatal West Nile virus infection after probable transfusion-associated transmission-Colorado 2012. MMWR Morb Mortal Wkly Rep 2013; 62:622-624.
14. Racsa L, Gander R, Chung W, et al. Clinical features of West Nile virus epidemic in Dallas Texas 2012. Diagn Microbiol Infect Dis 2014; 78:132-136.
15. Lindsey NP, Staples JE, Lehman JA, Fischer M. Medical risk factors for severe West Nile virus disease, United States 2008-2010. Am J Trop Med Hyg 2012; 87:179-184.
16. Levi ME. West Nile virus infection in the immunocompromised patient. Curr Infect Dis Rep 2013; 15:478-485.
17. Blau DM, Rabe IB, Bhatnagar J, et al. West Nile virus RNA in tissues from donor associated with transmission to organ transplant recipients. Emerg Infect Dis 2013; 19:1518-1520.
18. Josekutty J, Yeh R, Matthew S, et al. Atypical presentation of West Nile virus in a newly diagnosed human immunodeficiency virus patient in New York City. J Clin Microbiol 2013; 51:1307-1309.
19. Kumar M, Roe K, Nerurkar PV, et al. Impaired virus clearance, compromised immune response and increased mortality in type 2 diabetic mice infected with West Nile virus. PLoS One 2012; 7:e44682.
20. Cho H, Diamond MS. Immune responses to West Nile virus infection in the central nervous system. Viruses 2012; 4:3812-3830.
21. Suthar MS, Diamond MS, Gale M Jr. West Nile virus infection and immunity. Nat Rev Microbiol 2013; 11:115-128.
22. Netland J, Bevan MJ. CD8 and CD4 T cells in West Nile virus immunity and pathogenesis. Viruses 2013; 5:2573-2584.
23. Wang T, Welte T. Role of natural killer and gamma-delta T cells in West Nile virus infection. Viruses 2013; 5:2298-2310.
24. Errett JS, Suthar MS, McMillan A, et al. The essential and nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J Virol 2013; 87:11416-11425.
25. Quicke KM, Suthar MS. The innate immune playbook for restricting West Nile virus infection. Viruses 2013; 5:2643-2658.
26. Rossini G, Landini MP, Gelsomino F, et al. Innate host responses to West Nile virus: implications for central nervous system immunopathology. World J Virol 2013; 12:49-56.
27. + T cell-dependent clearance of West Nile virus from the central nervous system. J Virol 2013; 87:11401-11415.
28. Suthar MS, Brassil MM, Blahnik G, et al. A systems biology approach reveals that tissue tropism to West Nile virus is regulated by antiviral genes and innate immune cellular processes. PLoS Pathog 2013; 9:e1003168.
29. Durrant DM, Robinette ML, Klein RS. IL-1R1 is required for dendritic cell-mediated T cell reactivation within the CNS during West Nile virus encephalitis. J Exp Med 2013; 210:503-516.
30. You F, Wang P, Wang L, et al. ELF4 is critical for induction of type I interferon and the host antiviral response. Nat Immunol 2013; 14:1237-1246.
31. Cho H, Shrestha B, Sen GC, Diamond MS. A role for Ifit2 in restricting West Nile virus infection in the brain. J Virol 2013; 87:8363-8371.
32. Ramos HJ, Lanteri MC, Blahnik G, et al. IL-1beta signaling promotes CNS-intrinsic immune control of West Nile virus infection. PloS Pathog 2012; 8:e1003039.
33. Wang P, Bai F, Zenewicz LA, et al. IL-22 signaling contributes to West Nile virus encephalitis pathogenesis. PLoS One 2012; 7:e44153.
34. Sultana H, Neelakanta G, Foellmer HG, et al. Semaphorin 7A contributes to West Nile virus pathogenesis through TGF-beta1/Smad6 signaling. J Immunol 2012; 189:150-158.
35. Clarke P, Leser JS, Quick ED, et al. Death receptor mediated apoptotic signaling is activated in the brain following infection with West Nile virus in the absence of a peripheral immune response. J Virol 2014; 88:1080-1089.
36. + T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. J Virol 2012; 86:8937-8948.
37. Kumar M, Roe K, Orillo B, et al. Inflammasome adaptor protein apoptosis-inducing speck-like protein containing CARD (ASC) is critical for the immune response and survival in West Nile virus encephalitis. J Virol 2013; 87:3655-3667.
38. Nocon AL, Ip JP, Lim SL, et al. The bacteriostatic protein lipocalin 2 is induced in the central nervous system of mice with West Nile virus encephalitis. J Virol 2014; 88:679-689.
39. Helbig KJ, Beard MR. The role of viperin in the innate antiviral response. J Mol Biol 2014; 426:1210-1219.
40. Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA 2013; 310:308-315.
41. Thabet FI, Servinsky SE, Naz F, et al. Unusual case of West Nile virus flaccid paralysis in a 10-year-old child. Pediatr Neurol 2013; 48:393-396.
42. Soldatou A, Vartzelis G, Vorre S, et al. A toddler with acute flaccid paralysis due to West Nile virus infection. Pediatr Infect Dis J 2013; 32:1023-1024.
43. Stewart RD, Bryant SN, Sheffield JS. West Nile virus infection in pregnancy. Case Rep Infect Dis 2013; 2013:351872.
44. Sivakumar RR, Prajna L, Arya LK, et al. Molecular diagnosis and ocular imaging of West Nile virus retinitis and neuroretinitis. Ophthalmology 2013; 120:1820-1826.
45. Leis AA, Szatmary G, Ross MA, Stokic DS. West Nile virus infection and myasthenia gravis. Muscle Nerve 2014; 49:26-29.
46. Tesh RB, Siirin M, Guzman H, et al. Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J Infect Dis 2005; 192:287-295.
47. Saxena V, Xie G, Li B, et al. A hamster-derived West Nile virus isolate induces persistent renal infection in mice. PLoS Negl Trop Dis 2013; 7:e2275.
48. Murray K, Walker C, Herrington E, et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis 2010; 201:2-4.
49. Gibney KB, Lanciotti RS, Sejvar JJ, et al. West Nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus infection. J Infect Dis 2011; 203:344-347.
50. Barzon L, Pacenti M, Franchin E, et al. Excretion of West Nile virus in urine during acute infection. J Infect Dis 2013; 208:1086-1092.
51. Maxmen A. The hidden threat of West Nile virus. Nature 2012; 489:349-350.
52. Nolan MS, Podoll AS, Hause AM, et al. Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort. PLoS One 2012; 7:e40374.
53. Busch MP, Kleinman SH, Tobler LH, et al. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis 2008; 198:984-993.
54. Murray KO, Garcia MN, Yan C, Gorchakov R. Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus. Am J Trop Med Hyg 2013; 89:996-1000.
55. Carson PJ, Prince HE, Biggerstaff BJ, et al. Characteristics of antibody responses in West Nile virus seropositive blood donors. J Clin Microbiol 2014; 52:57-60.
56. Elseginy SA, Massarotti A, Nawwar GA, et al. Small molecule inhibitors of West Nile virus. Antivir Chem Chemother. [Epub ahead of print]
57. Lim SP, Shi PY. West Nile virus drug discovery. Viruses 2013; 5:2977-3006.
58. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-454.
59. Rodriguez-Pulido M, Martin-Acebes MA, Escribano-Romero E, et al. Protection against West Nile virus infection in mice after inoculation with type I interferon-inducing RNA transcripts. PLos One 2012; 7: e49494.
60. Dayan GH, Pugachev K, Bevilacqua J, et al. Preclinical and clinical development of a YFV 17D-based chimeric vaccine against West Nile virus. Viruses 2013; 5:3048-3070.
61. Dayan GH, Bevilacqua J, Coleman D, et al. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults >50 years of age. Vaccine 2012; 30:6656-6664.
62. Durbin AP, Wright PF, Cox A, et al. The live attenuated chimeric vaccine rWN/& DEN4delta30 is well tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine 2013; 31:5772-5777.
63. Li XF, Zhao W, Lin F, et al. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2. J Gen Virol 2013; 94:2700-2709.
64. Brandler S, Tangy F. Vaccines in development against West Nile virus. Viruses 2013; 5:2384-2409. Stroke